tirzepatide phase 3 study results Lilly's triple agonist delivers up to 71.2 lbs of weight loss An Observational Study of Cardiovascular

Adults with overweight or obesity lost more weight with the GIP/GLP-1 dual agonist tirzepatide than the GLP-1 receptor agonist semaglutide, according to findings published in JAMA Internal Medicine

By injecting Mounjaro, which combines the effects of both GIP and GLP, it is expected to affect the satiety center and suppress appetite

GLP-1 receptor agonistsmedicines such as semaglutide and liraglutideare increasingly prescribed for type 2 diabetes and weight management, but many survivors wonder whether these treatments are safe given their cancer history

Why not

W.EmotoC.FukudaT.MizunoT.MehtaP

The added activation of GIP receptors means tirzepatide can enhance the way your body processes sugar and fat